AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX202.13+1.35 (+0.67%) ▲|SBUX105.82-0.90 (-0.84%) ▼|SCHW110.38+2.14 (+1.98%) ▲|SO88.77+0.46 (+0.52%) ▲|SPG211.52+1.32 (+0.63%) ▲|T26.19+0.24 (+0.92%) ▲|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN253.83-0.97 (-0.38%) ▼|UBER75.96-0.49 (-0.64%) ▼|UNH400.94+1.28 (+0.32%) ▲|UNP289.15-0.58 (-0.20%) ▼|UPS103.50+0.49 (+0.48%) ▲|USB63.53+0.76 (+1.21%) ▲|V378.75+0.35 (+0.09%) ▲|VZ50.59+0.37 (+0.74%) ▲|WFC89.19-0.08 (-0.09%) ▼|WMT108.42+2.33 (+2.20%) ▲|XOM162.21-1.94 (-1.18%) ▼|AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX202.13+1.35 (+0.67%) ▲|SBUX105.82-0.90 (-0.84%) ▼|SCHW110.38+2.14 (+1.98%) ▲|SO88.77+0.46 (+0.52%) ▲|SPG211.52+1.32 (+0.63%) ▲|T26.19+0.24 (+0.92%) ▲|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN253.83-0.97 (-0.38%) ▼|UBER75.96-0.49 (-0.64%) ▼|UNH400.94+1.28 (+0.32%) ▲|UNP289.15-0.58 (-0.20%) ▼|UPS103.50+0.49 (+0.48%) ▲|USB63.53+0.76 (+1.21%) ▲|V378.75+0.35 (+0.09%) ▲|VZ50.59+0.37 (+0.74%) ▲|WFC89.19-0.08 (-0.09%) ▼|WMT108.42+2.33 (+2.20%) ▲|XOM162.21-1.94 (-1.18%) ▼|
28.2 C
New York
Friday, September 4, 2026

Tag: lung

newssourceFORcompanyinformationcontent1releasesmarket

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C.,...

Brayton Purcell LLP Highlights KQED Reporting on Federal Bill Affecting Artificial Stone Silicosis Claims

NOVATO, Calif., June 5, 2026 /PRNewswire/ -- Brayton Purcell LLP is bringing attention to a June 4, 2026 article by KQED News journalist Farida Jhabvala...

Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conference

New clinical findings further reinforce therapeutic potential of vapendavir as targeted approach to preventing rhinovirus-driven COPD exacerbationsWASHINGTON, June 5, 2026 /PRNewswire/ -- Altesa BioSciences, a...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

Herbalgy “TO-Go” Summer Treat: Keung To-Themed Gelato Truck

Free Gelato + Exclusive Fan Support Hand Fan, Stay Cool. Stay "TO". One Receipt, Triple Summer Rewards: Win The Herbalgy Trophy Tickets!HONG KONG, June 5, 2026...

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline –...

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces the reopening of the Lead Plaintiff appointment process in a pending securities class action lawsuit on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI). Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLung

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers